Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

ClinicalTrials.gov ID: NCT04818216

Public ClinicalTrials.gov record NCT04818216. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.

Study identification

NCT ID
NCT04818216
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
28 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2021
Primary completion
Dec 8, 2021
Completion
Jan 2, 2022
Last update posted
Dec 25, 2023

2021 – 2022

United States locations

U.S. sites
4
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Icahn School of Medicine at Mount Sinai New York New York 10029-6574
The University of Texas Health Science Center at San Antonio San Antonio Texas 78229
University Health Systems San Antonio Texas 78229
Harborview Medical Center Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04818216, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 25, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04818216 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →